Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Johns Hopkins

Neither a doctor nor a teaching hospital

Research payments

$4,183,480

90 payments

Through program year 2025, Johns Hopkins is reported as receiving $4,183,480 in research payments, across 90 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $448,485 5
2024 Research $585,164 4
2023 Research $381,615 11
2022 Research $760,139 14
2021 Research $1,303,050 31
2020 Research $370,506 15
2019 Research $334,522 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $2,592,046 23 payments
  2. Amgen Inc. $736,496 14 payments
  3. E.R. Squibb & Sons, L.L.C. $379,215 11 payments
  4. Guerbet LLC $189,336 2 payments
  5. Dilon Technologies, Inc. $93,369 4 payments
  6. Functional Neuromodulation Inc $31,934 1 payment
  7. TransMedics, Inc. $29,288 7 payments
  8. Myriad Genetic Laboratories, Inc. $28,314 2 payments
  9. Advanced Accelerator Applications $25,575 1 payment
  10. Promega Corporation $23,708 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Multi-agent low dose chemotherapy gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan followed by maintenance with olaparib and pembrolizumab in untreated metastatic pancreatic ductal adenocarcinoma $665,360 2 payments
  2. Phase 2 Study of GVAX Pancreas Vaccine with Cyclophosphamide, Pembrolizumab, and Epacadostat with or without CRS-207 in Patients with Metastatic Pancreatic Cancer $585,909 3 payments
  3. Tumor Microenvironment Features of Response to Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers $412,309 1 payment
  4. AMG 427 Ph1/2 AML $391,338 6 payments
  5. Phase I/II CTLA4-NF-Probody FIH Mono/Nivo Combo in advanced solid tumors $309,736 3 payments
  6. Phase 2b - Dose and Regimen Finding Study $259,189 4 payments
  7. STUDY NAME#Tumor Microenvironment Features of Response to Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers $212,576 1 payment
  8. Study of MK-3475 in Patients with Microsatellite Unstable (MSI) Tumors $170,447 5 payments
  9. A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects with Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination with Pembrolizumab in Subjects with Advanced Gastrointestinal Tumors $155,600 3 payments
  10. A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects with Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination with Pembrolizumab in Subjects with Advanced Gastrointestinal Tumors $119,500 2 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $189,336 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record